JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations

NCT04418167 · clinicaltrials.gov ↗

PHASE1

Phase

SUSPENDED

Status

71

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor decision

Conditions

Solid Tumors

Interventions

DRUG: JSI-1187
DRUG: Dabrafenib

Sponsor

JS InnoPharm, LLC